Why Moderna Stock Exploded 177% on One Cancer Trial Result

Why Moderna Stock Exploded 177% on One Cancer Trial Result

Moderna stock went up by 177% on August 19, 2026 after Moderna and Merck both released promising Phase 3 results for a personalized mRNA cancer vaccine in melanoma. This was one of the biggest one-day moves by any S&P 500 stock in the last several decades.

Most of the time, technology companies like Moderna are rarely in the news for a medical advancement. But, this story is just that... it is being described as the first major breakthrough in the development of oncology mRNAs, and the potential for a revolutionary change in cancer treatment and the creation of a separate revenue stream beyond Moderna’s existing COVID vaccine.

A simple overview of the case: INTerpath-001

The vaccine, referred to as Intismeran autogene (V940 or mRNA-4157), is administered to medically-removed Stage IIB-IV melanoma patients after surgery and prior to the administration of systemic therapy.

In the Phase III INTerpath-001 study, researchers verbally administered treatments to 1,137 subjects and compared the following treatments:

• Intismeran plus Keytruda (pembrolizumab)

• Keytruda alone (current standard adjuvant treatment).

At the pre-specified interim analysis, the combination treatment achieved all primary endpoints:

• Recurrence-free survival (RFS): time to tumor recurrence or death.

• Distant metastasis-free survival (DMFS): time to metastasis to distant organs or death.

The companies announced that the results achieved with the combination treatment demonstrated clinically significant and statistically better outcomes when compared to the treatment with Keytruda. The Keytruda treatment demonstrated statistically worse clinical outcomes. The precise hazard ratios and median survival times were not reported when the companies announced the interim results, as the independent data monitors declared the study completed.

What the cancer vaccine really means

Unlike vaccines for HPV or hepatitis B, this vaccine is not a preventative vaccine. It is a therapeutic vaccine developed specifically for each patient based on their tumor.

Here's how it works:

1. After the tumor has been surgically removed, it is sequenced to identify neoantigens. Neoantigens are mutations that are unique to the patient's cancer.

2. Machine Learning is used to identify 34 neoantigens.

3. Encoded in an mRNA vaccine, these neoantigens become the instructions that the vaccine uses to teach the immune system to recognize the cancer.

4. Keytruda is used to release the "brakes" on the T-cells.

In plain terms: Keytruda enables the T-cells to attack more aggressively, while Intismeran teaches them what to attack.

Earlier Phase 2b data had already suggested large risk reductions (about 49% lower risk of recurrence/death and 59% lower risk of distant metastasis/death vs Keytruda alone), which set the stage for this Phase 3 win.

Why the market reacted so violently

The surge of 177% can be attributed to the following three key factors:

1. The first of its kind, the late-stage proof, of an mRNA cancer vaccine

Until now, mRNA's big success story was COVID vaccines. This is the first time an mRNA cancer vaccine has succeeded in a large, late-stage trial, validating the entire approach for oncology and opening doors for similar therapies in other cancers.

Until recently, mRNA has only been known to help with the development of COVID vaccines. For the first time, a large, late-stage trial of an mRNA cancer vaccine provides proof of the concept and validates the approach for oncology, and also provides a precedent for new cancer therapies.

2. A new growth engine for Moderna

Moderna's COVID vaccines have lost value over time. A successful cancer vaccine could help Moderna develop other new cancer therapies, and also help Moderna reach its original valuation before the pandemic.

It was reported that Moderna's market cap increased some 25 billion to about 69 billion USD over the course of an hour, which equates to about 44 billion USD of newly issued value.

3. A bumper short squeeze

Many investors had bet against Moderna, expecting continued struggles. The surprise success triggered a short squeeze, with estimates of around 5.5 billion USD in one-day losses for short sellers, and year-to-date short losses on the trade rising to roughly 7.7 billion USD.

Many had it in for Moderna and placed their bets against it, assuming it would continue its struggles. After some shocking announcement successes, short sellers lost roughly $5.5 billion dollars in a day amidst a short squeeze and, year to date, the short trade on Moderna’s stock has hemorrhaged an additional $2.2 billion dollars.

Merck’s stock moved up over 10-12% as well because the regimen is built on Keytruda, its blockbuster immunotherapy.

Safety profile and regulatory next steps

Moderna and Merck gave no new updated safety concerns. In the previous reports, almost the entirety of the side effects from the vaccine were mild to moderate. While relatively fit post-surgery patients would be the expected demographic for this drug's use, these symptoms would make it an acceptable side effect profile.

Next steps include:

• Reporting to an upcoming international medical meeting comprehensive data.

• Communicating with the U.S. FDA and other regulatory bodies about the filing of Intismeran plus Keytruda and possible timelines for approval that could be as early as 2027.

• Continuing to monitor patients for overall survival(OS) and other long horizon endpoints.

Beyond melanoma: what's in store with the rest of the pipeline?

The melanoma result is just the first of many expected. Moderna and Merck have many more follow-up trials for Intismeran and Keytruda across other cancer indications, such as:

• Non-small cell lung cancer (NSCLC) - in the adjuvant setting

• Bladder/kidney (renal cell) cancers - in the advanced setting

• Early, or proof-of-concept, efforts in stomach (gastric) and pancreatic cancers

• Currently, studies in colon cancer are ongoing with results anticipated in 2027 and in pancreatic cancer later in the decade.

Analysts view this as the potential start of a trend of personalized cancer vaccines, if melanoma success is extrapolated to the other tumor types.

How it impacts Indian Retail Investors

If you are an Indian retail investor tracking global Biotech/Healthcare stocks:

• Direct exposure: Most Indian retail investors like you cannot buy US stocks directly without using an LRS-enabled Demat account/remittance route and tackling forex, taxes and compliance. Such investments should be treated as high-risk and long term. For context on account types, see our guide on the difference between trading and Demat accounts.

• Indirect exposure: Some Indian mutual funds and ETFs have exposure to global healthcare/ biotech themes, but check underlying holdings; many do not hold Moderna or Merck directly.

• Thematic lesson: This shows even binary outcomes of a clinical trial chaotic movement of biotech stocks where traders profit at the expense of long term holders who do not understand the trial’s full pipeline.

For most retail investors, this event should serve as an educational lesson towards evaluating the impacts of clinical trial outcomes and what the next phase of the trial indicates and how the company is valued as a result.

Risks & reality

While the potential benefits of Intismeran autogene are exciting, we must be cautious with some of the following:

• As an investigational therapy: Several positive Phase 3 results do not guarantee regulatory approval and/or successful commercialization.

• As a financial investment: As the manufacturing of personalized vaccines is complex and costly, this may impact their availability and reimbursement.

• As a business risk: Success in melanoma does not guarantee success for lung, pancreatic, or other cancers. There are distinct biologies which will impact the challenges of tumor-specific trials.

• As an investment risk: A move of 177% is setting a very high bar; even delays in regulatory filings, manufacturing, or other future trials, may result in a sharp decline.

For retail investors, this is a textbook scenario of understanding the educational value over the opportunity of chasing momentum.